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= 2.34, 95% IC = [1.01; 5.39]) and TO--- groups (OR = 2.99,
95% CI = [1.26; 7.08]).The trend in CV risk between the three
TO groups was signiﬁcantly increased (p = 0.02). CONCLU-
SION: This study conﬁrms that inadequate LDL-cholesterol goal
attainment in high CV risk patients treated with LLD is associ-
ated with an increased risk of cardiovascular morbidity. Our
results strongly support the necessity of a better adherence to
guidelines to improve cardiovascular prevention.
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OBJECTIVES: Determine what variables can be used in a phar-
macy claim database to develop a predictive model and to 
identify patients who are likely to be poorly compliant with
statin treatment at the time of the initial statin prescription.
METHODS: The sample includes 22,767 patients over the age
of 18 who were continuously eligible for at least two-years. The
patients are all new statin users as deﬁned by a one-year wash-
out period before the ﬁrst statin prescription. All patients have
one year of data after the ﬁrst statin prescription. Pharmacy
claims in the year before the ﬁrst statin prescription, along with
demographic and health plan information are used to construct
three predictive models, based on three different. METHODS:
1) logistic; 2) classiﬁcation tree; and 3) neural network. Com-
pliance was measured with the medication possession ratio
(MPR), and predictive power was determined with the area
under the receiver operating curve (AUC). Models were created
with an analysis set of 12,767 patients and validated on the
remaining 10,000 patients. Each AUC is computed from the test
sample. RESULTS: The most signiﬁcant predictors are: age less
than 40, having more than 30 total claims, having a large pro-
portion of reﬁll claims (over 60%) as opposed to new prescrip-
tions, using drugs for anxiety and tension, and being treated for
glaucoma. We compared the AUC generated by predicting high
compliance as deﬁned by a MPR greater than 0.8 with each
model. All models demonstrated a similar predictive power, 
with neural networks performing better at predicting high com-
pliance (AUC = 0.62) then classiﬁcation tree (AUC = 0.61) and
logistic regression (AUC = 0.57). CONCLUSION: Despite the
limited predictability of compliance in patients new to statin
treatment, accurate models can be developed using only phar-
macy claims.
CARDIOVASCULAR DISEASE—Hypertension
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OBJECTIVES: Comorbidity often is an important confounder in
health outcomes studies. Although a number of comorbidity
measurements are available, little is known about their perfor-
mance in studies in which health expenditures are the primary
outcome. This study compares the performance of the Elixhauser
Index and Charlson Index as well as remedial measurements of
annual prescription use and physician visits in predicting health
expenditures. METHODS: The study population included
19,793 members of a managed care organization who received
a new prescription for an antihypertensive medication in 2002.
Elixhauser and Charlson scores were derived from hospital
claims occurring in the year preceding this encounter. The sum
of physician’s visits and prescription ﬁlls were calculated simi-
larly. The primary prediction outcome was the log transformed
sum of prescription, physician, and hospital expenditures in the
year following the encounter. Performance was determined by
ﬁtting linear regression models and examining R2 statistics.
RESULTS: A greater proportion of regression model variance
was explained by the Charlson Index (R2 = 0.0989) than the 
Elixhauser Index (R2 = 0.0665). The remedial measurements 
of number of prescriptions ﬁlled (R2 = 0.1413) and number of
physician’s visits (R2 = 0.1295) per year appears better at pre-
dicting future health expenditures than the comorbidity indices
examined. The addition of age and gender to the model increases
the explained proportion of variance for each measurement. The
addition of number of prescriptions, number of physician’s visits,
age, and gender maximizes the explained proportion of variance
for the Charlson Index model (R2 = 0.2526) and Elixhauser
Index model (R2 = 0.2135). CONCLUSION: The Charlson
Index appears to outperform the Elixhauser Index as a comor-
bidity control in health expenditure studies. However, compared
to the remedial measurements of number of prescriptions ﬁlled
and number of physician visits per year these indices appear 
inferior.
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OBJECTIVES: To assess prevalence, awareness, and control of
hypertension in a Latino population in Los Angeles County, CA,
USA. METHODS: Data included 6118 subjects and were
obtained from the Los Angeles Latino Eye Study (LALES), a 
population-based study originally developed to assess the preva-
lence of eye disease and self-reported visual functioning in
Latinos aged 40 or more years. Hypertension history was
reported by participants and blood pressure clinical values were
assessed by two measurements during a clinical exam. Subjects
self-reporting hypertension were deﬁned as aware of their con-
dition and were considered controlled if measured blood pres-
sure values were, on average, lower than 140/90mmHg or
130/80mmHg for diabetics. T-tests and Chi-square tests were
used to test for signiﬁcant differences between groups on demo-
graphic, socioeconomic and access to care variables. RESULTS:
In this population, prevalence of hypertension was 42.4%
(2592/6118). Prevalence was not statistically different between
men and women (p = 0.6773) but increased with age (p <
0.0001). Univariate analyses showed that the percentage of sub-
jects with hypertension also differed signiﬁcantly (p < 0.05) by
obesity status, number of comorbidities, place of birth, marital
and employment statuses, acculturation, education and income
levels, and by access to care variables (usual clinic, doctor and
health insurance). Seventy-two percent of people with hyperten-
sion were aware of it (1855/2592). Awareness was signiﬁcantly
higher among women (76% vs. 64%, p < 0.0001) but increased
with age in men (p < 0.0001). Awareness also varied by number
of comorbidities, place of birth, employment status, and access
to care variables. Finally, only 22% (420/1855) of subjects aware
of having high blood pressure were considered as controlled after
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measurements of clinical values. CONCLUSIONS: Almost 75%
of subjects with hypertension were aware of it. However, control
rate was relatively low in this Latino population, suggesting 
a need for community-based programs targeting hypertensives
unaware of their diagnosis.
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OBJECTIVE: To know the cost implications of antihypertensive
therapy to society. METHOD: Cost of Illness Analysis was used
for Out-Patients. Drug review was carried out retrospectively for
randomly sampled 39 case notes over a one-year period. The fol-
lowing were collected; number of hospital visits, BP at each visit,
drugs prescribed at each visit. Cost components were the direct
medical costs. These include the total cost of drugs over one-year
period, personnel cost, diagnostic costs, and transport cost. Hos-
pital cost of the drugs were used and the cost per deﬁned daily
dose of each drug was calculated as well as the total drug cost
for one year. Stop-watch-time studies and monthly earnings were
used in the calculation of personnel costs for each patient bearing
in mind the number of visits. Since the study covers a one-year
period (July, 2003–July, 2004), neither discounting nor inﬂation
were considered in the analysis. RESULTS: Combination therapy
was used for all patients. Total cost of therapy for the 39 patients
over a one year period = N1,391,528.35 (US$9939.49), 90.4%
(N1,258,139.35; US$8986.71) of which was for drugs. Average
cost per patient = N35,680.21, range of cost; N1,026.80 and
N84,395.15. With prevalence of hypertension in Nigeria esti-
mated to be 10%–12% (132.8 million according to UNDP
2004); total Cost of Illness associated with hypertension less the
indirect costs among others not considered could be in the range
of N473,142,628,800.00 i.e. over N450 billion (over US$3.38
billion) per annum. CONCLUSION: The cost of illness due to
hypertension is quiete high, particularly in a country where
70.2% (93.2 million) of people live below the poverty line
(earning less than US$1 (N140) per day. Urgent measures need
to be taken not only for more cost effective therapy, but also to
increase awareness and prevention of hypertension among
others.
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OBJECTIVES: To determine the relationships between patient
education and patient adherence and hypertension control in
patients in two primary care outpatient practices in an academic
medical center. METHODS: As part of an outpatient quality
measurement and improvement project, data was collected for
2003 on a random sample of 384 patients ages 45–85, through
use of billing data and medical record review. In addition to the
outcome variable of hypertension control, measured using mod-
iﬁed Health Plan Employer Data and Information Set (HEDIS)
speciﬁcations, data were collected on patient demographics, 
co-morbidities, medications, education, and adherence factors.
First, bivariate chi-square tests were performed to assess the rela-
tionship between hypertension control and each hypothesized
patient education or adherence factor. Then, a logistic regression
was performed to assess the independent relationship between
the odds of hypertension control and each patient education or
adherence factor, controlling for potentially confounding effects
of age, gender, and race. RESULTS: In the bivariate analyses, as
hypothesized, hypertension control was signiﬁcantly associated
with documented instruction/information regarding lifestyle
modiﬁcations (chi-square = 3.84, df = 1, p = 0.050), mention of
patient’s overall compliance to therapy (chi-square = 4.47, df =
1, p = 0.034), patient’s compliance to medical therapy (chi-
square = 9.11, df = 1, p = 0.002), and patient’s compliance to
lifestyle modiﬁcations (chi-square = 5.98, df = 1, p = 0.014). In
the logistic regression, while the overall model was statistically
signiﬁcant (chi-square = 17.70, df = 8, p = 0.024), none of the
hypothesized effects was signiﬁcant. However, two of the effects
approached signiﬁcance: compliance to medical therapy (chi-
square = 2.86, df = 1, p = 0.091; OR = 1.887, CI = 0.904–3.941)
and patient’s compliance to lifestyle modiﬁcations (chi-square =
2.83, df = 1, p = 0.050; OR = 2.188, CI = 0.999–4.791). CON-
CLUSIONS: Given the results of tests of hypotheses about effects
of patient education and adherence on hypertension control in
two primary care outpatient practices in an academic medical
center, additional quality improvement interventions and
research are justiﬁed to further specify the potential beneﬁts of
patient education and provider encouragement of patient 
adherence.
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OBJECTIVES: Antihypertensive medications are important in
saving lives and decreasing disability. Formulary tiers, which
determine copayment levels, may contribute to patients taking
antihypertensive medications incompletely, inconsistently, or not
at all, diminishing the potential beneﬁt of treatment. Our objec-
tive was to determine whether copayment level is related to
adherence to antihypertensive medications. METHODS: A ret-
rospective claims database evaluation of hypertensive patients in
a large health plan in Hawaii between January, 1999 and June,
2004 (n = 114,232) was conducted. Generic copayments were
$5, preferred brand copayments were $20, and copayments for
non-preferred brands varied based on price with copayments
ranging from $20–$165. Adherence was measured using med-
ication possession ratios, with a ratio of 0.8 considered adher-
ent. Adherence rates were calculated annually from the date of
ﬁrst prescription for up to three years. Multi-variable logistic
regression was used to examine the impact of copayment on
adherence, controlling for patient characteristics and speciﬁc
therapeutic class. RESULTS: Overall, adherence was 66.8% for
generics, 66.1% for preferred brands, and 54.6% for non-
preferred brands. Differences in adherence between generic 
and preferred brands for speciﬁc classes were 4–7% and 9–18%
for preferred and non-preferred brands. The largest difference in
adherence was between generic and non-preferred beta blockers
(22%). All the differences were statistically signiﬁcant at the 0.05
level. CONCLUSION: Adherence rates were consistently highest
for generic drugs, and lowest for non-preferred brands for all
speciﬁc therapeutic classes. This suggests that copayment, which
is directly tied to formulary tier, may play a signiﬁcant role in
adherence to antihypertensive medication.
